[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100192097":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":50,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":80,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Weill Medical College of Cornell University","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"1.1 HEALTHY SUBJECTS",null,"Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.",{"label":13,"type":10,"description":14,"interventionNames":10},"1.2 SUBJECTS WITH LUNG DISEASE","Defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population)",{"label":16,"type":10,"description":17,"interventionNames":10},"2. WCMC\u002FNYPH CLINICAL PATIENTS","Subjects may be recruited if subjects fit inclusion\u002Fexclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit.\n\nWCMC\u002FNYPH clinical patients will not undergo any additional procedures listed in this protocol as part of this research study.",{"label":19,"type":10,"description":20,"interventionNames":10},"3. PCNY CLINICAL PATIENTS","Subjects may be recruited if subjects fit inclusion\u002Fexclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit. Clinical patients seen at the Pulmonary Consultants of New York will only undergo the nasal sample collection and may be asked to have a blood draw of about 2 teaspoons (9ml).",[22],{"name":23,"affiliation":5,"role":24},"Ronald G. Crystal, M.D.","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Niamh Savage","CONTACT","12127460284","nis2049@med.cornell.edu",[32],{"facility":33,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine","RECRUITING","New York","10065-4870","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-74.00597,40.71427,{"lat":43,"lon":42},[46],{"name":27,"role":28,"phone":47,"phoneExt":10,"email":30},"212-746-0284",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51,54,57],{"name":52,"class":53},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"name":55,"class":56},"Boehringer Ingelheim","INDUSTRY",{"name":58,"class":6},"Cystic Fibrosis Foundation","100192097","collection-of-airway-blood-andor-urine-specimens-from-subjects-for-research-studies-100192097",false,"NCT01776398","Collection of Airway, Blood and\u002For Urine Specimens From Subjects for Research Studies","Inclusion Criteria:\n\nGroup 1.1 - HEALTHY VOLUNTEER RESEARCH SUBJECTS (Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population. Smoking status is defined for individuals that may use any of the following: cigarettes, pipes, E-cigarettes, waterpipe, shisha, etc.):\n\n* All study subjects should be able to provide informed consent\n* Males or females ages 18 years and older\n* Must provide HIV informed consent\n\nGroup 1.2 - VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE (As defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population. Smoking status is defined for individuals that may use any of the following: cigarettes, pipes, E-cigarettes, waterpipe, shisha, etc.):\n\n* Must provide informed consent\n* Males and females age 18 years and older\n* Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and\u002For (6) diseases of organs with known association with lung disease\n* Must provide HIV informed consent\n\nAdditional Inclusion criteria for CF subjects:\n\n• All CF subjects will be homozygous for the ΔF508 mutation, with mild-moderate lung disease as defined by FEV1 ≥ 50%\n\nGroup 2 - WCMC\u002FNYPH CLINICAL PATIENTS\n\n* Must provide informed consent\n* Males and females, age 18 years and older\n* Lung disease proven by at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) diseases of organs with known association with lung disease, and (7) individuals with the blood eosinophil levels of 5% or greater.\n\nGroup 3 - PCNY CLINICAL PATIENTS VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE\n\n* Must provide informed consent\n* Males and females, age 18 years and older\n* Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) diseases of organs with known association with lung disease\n\nExclusion Criteria:\n\nGroup 1.1 - HEALTHY VOLUNTEER RESEARCH SUBJECTS\n\n* Individuals not deemed in good overall health by the investigator during screening visits and\u002For prior to the bronchoscopy will not be accepted into the study.\n* Individuals with history of chronic lung disease, including asthma or with recurrent or recent (within three months) acute pulmonary disease will not be accepted into the study.\n* Individuals with allergies to atropine or any local anesthetic will not be accepted into the study.\n* Individuals with allergies to pilocarpine, isoproterenol, terbutaline, atropine or aminophylline will not be accepted into the study.\n* Females who are pregnant or nursing will not be accepted into the study\n\nGroup 1.2 - VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE\n\n* Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, pilocarpine, isoproterenol, terbutaline, aminophylline, or any local anesthetic will not be included in the study\n* Individuals deemed unable to complete the bronchoscopy due to health concerns by the investigator.\n* Females who are pregnant or nursing\n\nAdditional Exclusion criteria for CF subjects:\n\n* Experienced a recent (≤ 8 weeks) pulmonary exacerbation of their disease\n\nGroup 2 - WCMC\u002FNYPH CLINICAL PATIENTS\n\n* Patient refuses consent\n\nGroup 3 - PCNY CLINICAL PATIENTS\n\n* Patient refuses consent",true,"ALL","18 Years",{"count":69,"type":70},2000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to obtain biologic materials from the blood, airways and\u002For urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters. These provide control information when compared to individuals with various pulmonary diseases, and will help in understanding of the etiology and pathogenesis of various lung diseases. The underlying hypothesis is that the pathologic morphological changes in the airway epithelium must be preceded by changes in the gene expression pattern of the airway epithelium and potentially in macrophages.",[74,75,76,77,78,79],"Chronic Obstructive Pulmonary Disease (COPD)","Smoking","Smoking Cessation","Idiopathic Pulmonary Fibrosis (IPF)","Rheumatoid Arthritis-Associated Interstitial Lung Disease","Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)",[81,82,83,84,75,85,86,87,88,89,90,91,78,92],"COPD","Chronic Obstructive Pulmonary Disease","Lung disease","Emphysema","Healthy Smoker","Smoker","Non-smoker","IPF","RA-ILD","SSC-ILD","Idiopathic Pulmonary Fibrosis","Scleroderma-Associated Interstitial Lung Disease","2025-11-12",{"date":95,"type":96},"2025-11-14","ACTUAL",{"date":98,"type":96},"2012-08-29",{"date":100,"type":70},"2028-12",{"name":5,"class":6},1]